Background: Morning blood pressure (BP) peak may be a risk factor for cardiovascular disease. Whether morning BP should be a target of hypertension treatment is not known. We investigated the relationship between morning BP variations, carotid internal-medial thickness (CIMT), circulating inflammatory markers, and sympathetic activity in hypertensive patients with different patterns of morning BP increase at baseline and after antihypertensive treatment.
M
any studies in the past decade have demonstrated diurnal variation in the onset of acute cardiovascular disorders in hypertensive patients, such as acute coronary syndrome, 1 cardiac arrhythmias, 2 and sudden cardiac death. 3 The results consistently showed an increased incidence of acute cardiac events in the morning hours (between 6 AM and noon) and a low incidence at night. Blood pressure (BP) increases during the night because of the reduction of sympathetic activity that is brought about by sleep, and then increases steeply when in the morning the subject awakes and resumes his/her daily activities. 4 This increase occurs together with a peak incidence of myocardial infarction and sudden death cardiac in the morning hours. 5 Moreover, recent prospective study suggests that higher morning BP surge might be an independent risk factor of cerebrovascular disease beyond ambulatory BP and nocturnal BP decreases. 6 The mechanisms associating morning BP peak and vulnerable atherosclerotic plaques are not clear, although several phenomena potentially dangerous for the heart, such as heart rate, fibrinolytic activity, platelet aggregability, and sympathetic activity, also show peak adverse modifications in the morning. 7, 8 This study was conducted to assess the relationship of morning BP to carotid intima-media thickness (CIMT), a validated surrogate cardiovascular end point, 9 circulating inflammatory markers (interleukin-6 [IL-6], interleukin-18 , and C-reactive protein [CRP] ), and sympathetic activity in a representative population of never-treated subjects with essential hypertension and with different patterns of morning BP increase. The study also addressed the question whether pharmacologic interventions that target higher morning BP provide unique benefits relative to other pharmacologic therapies that lower clinic BP comparably. We therefore compared the effects of two antihypertensive medications, a nonselective ␤-adrenergic antagonist with ␣-adrenergic-blocking activity carvedilol and a ␤ 1 -selective antagonist metoprolol, known to have different efficacy on sympathetic inhibition. 10 
Methods

Subjects
Hypertensive patients, attending for this trial conducted from January 1998 to June 2002, were recruited from the outpatient department for hypertension of the teaching hospital at the Second University of Naples, Italy. Among them we selected those with a diagnosis of essential hypertension, never treated with antihypertensive drugs. All subjects had a clinic systolic BP 140 mm Hg or diastolic BP 90 mm Hg on at least three visits at 1-week intervals and fulfilled all of the following inclusion criteria: no clinical or laboratory evidence of heart failure, coronary heart disease, previous stroke, valvular defects, obesity, or secondary causes of hypertension; high-quality echocardiographic tracings; and at least one valid BP measurement per hour during 24 h during ambulatory BP monitoring (ABPM). To exclude coronary heart disease, exercise testing, thallium scintigraphy, or both were performed when clinically indicated. The study was approved by the Ethics Committee of our Institution and informed written consent was obtained from each patient.
24-h ABPM
After the initial screening visit, ABPM was performed in all hypertensive patients. A physician measured clinic BP with a mercury sphygmomanometer in the hospital clinic before the beginning of ABPM, with the subject sitting for at least 10 min. The arm with higher BP values at office evaluations was chosen for the ABPM, which was performed with Dyna Pulse 5000A (Pulse Metric, Inc., San Diego, CA). Normal daily activities were allowed and encouraged, and subjects were told to keep their nondominant arm still and relaxed at their side during measurements. Readings were obtained automatically at 15-min intervals from 6 AM to 10 PM and at 30-min intervals from 10 PM to 6 AM by oscillometric technique. To abide by the actual wakefulness-sleep rhythm reported in subjects' diaries, we defined daytime between 10 AM and 10 PM and night-time between 1 AM and 6 AM. The morning BP peak was defined as an increase in systolic BP Ն50 mm Hg or diastolic BP Ն22 mm Hg (90 percentile of normotensive patients) during the early morning (6 to 10 AM), arbitrarily defined as the morning period, obtained from the mean of BP during the first 2 h after waking (eight BP readings) minus the mean BP during the night. The normal values (mean Ϯ SD) of morning BP peak obtained from 18 normotensive patients 45 Ϯ 6 years of age were as follows: systolic, 21 Ϯ 5 mm Hg; diastolic, 12 Ϯ 4 mm Hg. 8 In addition, the morning BP surge was also calculated in another two ways: sleep-trough morning BP surge, defined as the morning systolic BP minus the lowest systolic BP; and prewaking morning BP surge, defined as the morning systolic BP minus the preawake systolic BP. Morning BP was defined as the average of systolic BP during the first 2 h after wake-up time (eight BP readings). The lowest BP was defined as the average BP of three readings centered on the lowest night-time reading. Preawake BP was defined as the average BP during the 2 h just before wake-up time (four BP readings). Subjects without a morning BP peak were defined as MPϪ group and the others as MPϩ group. Subjects with a nocturnal reduction of systolic or diastolic BP of 10% were defined as dippers and the others as nondippers. Night-time workers, subjects going to bed later than 1 AM, and patients with sleep disordered breathing were excluded from the present study. Therefore, all study subjects were in bed during the entire night-time period and were awake and active during the morning and daytime interval. The 128 MPϩ hypertensive patients enrolled in the study were compared with 196 MPϪ hypertensive patients matched for age, sex, and body mass index.
Sympathetic Activity
Urinary catecholamines (epinephrine and norepinephrine) were measured with high-pressure liquid chromatography. Separate urine samples were obtained during the morning (6 to 10 AM), daytime (10 AM to 10 PM), and night-time (10 PM to 6 AM). Samples were immediately centrifuged at 3000 rpm for 15 min, urine and plasma were decanted and stored at Ϫ80°C until analysis.
Carotid B-mode Ultrasound
Carotid sonography was performed on a single ultrasound machine (Aloka 5500, Western Diagnostics, Inc., Evergreen, CO) with a 7.5-MHz sector scanner probe. Baseline and follow-up studies were performed in a standard fashion by a single specialist physician who was specifically trained to perform the prescribed study examination and was blinded to the presence of morning BP peak. All images were electronically stored. The measurement was made in the 1-cm segment proximal to the dilation of the carotid bulb and always in plaque-free segments. For each patient, three measurements on both sides were performed, on the anterior, lateral, and posterior projection of the far wall; the readings were then averaged. Paired CIMT measurements in the same arteries showed a high degree of reproducibility, with a mean difference in CIMT of 0.020 mm, and an intraclass correlation coefficient of 0.97 (P Ͻ .0001).
Laboratory Analysis
Plasma glucose and serum lipids were measured by enzymatic assays in the hospital's chemistry laboratory. Serum samples for inflammatory markers were stored at Ϫ80°C until assay. Serum concentrations of IL-6 and IL-18 were determined in duplicate with commercially available kits (Quantikine HS, R&D Systems, Minneapolis, MN). All samples for the same patient were measured in the same assay. The interassay coefficient of variation was Ͻ6% for all kits. High-sensitivity CRP was assayed in duplicate by immunonephelometry on Behring Nephelometer 2 (Dade Behring, Marburg, Germany).
Randomized Trial
This study was performed in the hypertensive patients with a morning BP peak (n ϭ 128). After 1 month of treatment with placebo and dietary counselling, patients were randomly assigned to open-label treatment with either carvedilol or metoprolol using a computer-generated random number sequence. Allocation was concealed in sealed study folders that were held in a central, secured location until after informed consent was obtained. The study protocol comprised a screening visit to assess patient eligibility, a titration period of 6 to 12 weeks for optimization of clinic BP in the metoprolol group, and for optimization of both clinic and morning BP in the carvedilol group, and a subsequent 12-month treatment period on optimal therapy. In the metoprolol group, the daily dosages were 10 mg (dose 1) or 20 mg (dose 2), taken once at bedtime; in the carvedilol group, daily dosages were 12.5 mg (dose 1) or 25 mg (dose 2), taken once at bedtime. The goals of the intervention were clinic BP equal or less than 130/85 mm Hg and morning BP equal or less than 140/90 mm Hg. Target BP values were achieved by adding hydrochlorothiazide to dose 2 as needed, the daily dosage was 12.5 mg (dose 3) or 25 mg (dose 4) taken once in the morning. All patients received standard dietary counseling by a study investigator in accord with the dietary recommendations of the Seventh Report of the Joint National Committee on treatment of hypertension. 11 The 108 MPϩ patients who completed the 12-month study demonstrated compliance with the treatment program through monthly return visit for prescription refills and clinic visits. The ABPM, 24-hour ambulatory electrocardiogram, and carotid sonography were performed at 6 and 12 months of the study. The primary outcome of the trial was the change in mean CIMT and serum concentrations of inflammatory markers after 1 year.
Statistical Analysis
Data are presented as mean Ϯ SEM unless stated otherwise. Baseline comparison was made using a t test and a nonparametric test as appropriate. The correlation of selected variables to CIMT was assessed using Pearson or Spearman correlation coefficients, as appropriate, and a stepwise multiple regression analysis was then used to evaluate the independent association of these variables with CIMT. In the randomized trial, data were analyzed by intention-to-treat on all randomized subjects. Changes of IL-6, IL-18, and CRP over time were evaluated using either a paired t test or Wilcoxon signed-rank test, as appropriate. Comparison of the treatment effect between experimental groups for the changes in the primary outcome at 12 months was performed with a t test for independent groups. The 2 test was used for comparing proportions of patients in the two groups that demonstrated regression of mean CIMT. All statistical analyses were performed using SPSS software (version 10.05, SPSS Inc., Chicago, IL).
Results
Anthropometric characteristics, routine blood chemical analyses, sleep duration, and clinic BP were similar in both MPϩ and MPϪ groups (Table 1) . Physical and mental activities, described in diaries (location, posture, activity, interactions, and mood) were not different between groups (data not shown). The BP increased steeply after waking up in both groups; however, the MPϩ group had a significant increase in both systolic and diastolic BP compared with the MPϪ group (P Ͻ .01) during the whole morning period. The daytime and the night-time profile did not significantly differ between the two groups ( Table 1 ). There were 20 nondippers in the MPϩ group (16%) and 35 in the MPϪ group (18%, P ϭ not significant).
Compared with the MPϪ patients, MPϩ patients had higher CIMT as well as CRP, IL-6, and IL-18 levels ( Table 1) . Both systolic and diastolic morning BP increases were positively correlated with CIMT (r ϭ 0.49 and r ϭ 0.43, respectively, P Ͻ .001) and CRP (r ϭ 0.38 and r ϭ 0.36, respectively, P Ͻ .01), as well as with IL-18 (r ϭ 0.45 and r ϭ 0.41, respectively, P Ͻ .001) and IL-6 (r ϭ 0.44 and r ϭ 0.37, respectively, P Ͻ .005).
Urine flow did not differ between the morning, diurnal, and nocturnal collection between the two groups ( Table 1) . In the MPϪ patients, catecholamine urinary output was significantly lower (Ϫ29% for both, P Ͻ .02) during the morning period compared with MPϩ patients (Table 1) , whereas, diurnal and nocturnal catecholamine output was not different (Table 1) .
In a multiple regression analysis, both systolic and diastolic morning BP increases were significant predictors of CIMT (adjusted R 2 ϭ 0.49, P Ͻ .005), whereas inclusion of age, physical activity, and metabolic parameters did not add explanatory information. Moreover, urinary catecholamine levels were significantly correlated with CIMT values (P Ͻ .01 to Ͻ .05).
Awake and morning systolic BP were significantly higher in the MPϩ group than in the MPϪ group (P Ͻ .01). The mean Ϯ SD sleep-trough morning BP surge defined by the difference between the morning systolic BP and the lowest systolic BP was 62 Ϯ 9 mm Hg for the MPϩ group and 21 Ϯ 9 mm Hg for the MPϪ group, and prewaking morning BP surge (defined by the difference between morning systolic BP and preawake systolic BP) was 31 Ϯ 7 mm Hg for the MPϩ group and 11 Ϯ 6 mm Hg for the MPϪ group.
Intervention Study
Eight patients of the carvedilol group and 12 patients of the metoprolol group prematurely withdrew from the study because of protocol noncompliance. The two groups (carvedilol, n ϭ 56, metoprolol, n ϭ 52) had similar baseline characteristics ( Table 2 ). The percentages of participants on monotherapy (dose 1 or 2) or bitherapy (dose 3 or 4) did not differ between groups (Table 2) . There was a similar course in clinic BP during the study in both groups (Table 3) , whereas the morning BP decreased significantly more among the patients in the carvedilol group (P Ͻ .01) (Fig. 1) . Reduction of clinic BP to Յ130/85 mm Hg was attained in 39% of metoprolol and in 41% of carvdilol group, whereas, reduction of morning BP to Յ140/90 mm Hg was achieved less consistently by metoprolol than carvedilol (19% v 54% of patients, P Ͻ .005). No significant changes from baseline in antropometric parameters, electrolytes, glucose, and lipid concentrations occurred in both groups (data not shown). Carvedilol resulted in significantly greater reduction of heart rate and urinary catecholamines than metoprolol (Table 3) . Compared with metoprolol, carvedilol caused significantly greater reductions in IL-6, IL-18, and CRP concentrations (Fig. 2) . Changes in IL-6, IL-18, and CRP concentrations after treatment were related to reductions in morning BP peaks (r ϭ 0.35, P Ͻ .001, r ϭ 0.26, P Ͻ .02, respectively; Table 4) in both groups, but not to changes in clinic BP. The CIMT decreased significantly in both groups, with a significant difference for carvedilol (P Ͻ .02) (Fig. 3) . Changes in morning BP after carvedilol treatment were associated with improvements in CIMT (Table 4) . After carvedilol treatment, the decline in serum IL-6 and CRP levels, as well as urinary catecholamine output and heart rate correlated with the changes in CIMT (Table 4) . Similar results were found for both the right and left CIMT when analyzed separately. The CIMT regression, defined as a net decrease in mean CIMT at 12 months, was observed in 49% of patients on carvedilol and in 18% of patients on metoprolol (P Ͻ .01). There was no difference observed between treatment groups in any of the 6-month CIMT measurements. To evaluate the independent association of changes in CIMT with changes in BP parameters, a multivariate analysis was performed in which CIMT was the dependent variable, and clinic BP, morning BP peak, morning urinary catecholamines, heart rate, IL-6, IL-18, and CRP were the independent variables. The model explained about the 65% of the variability in the change of CIMT with changes of morning BP peak, morning urinary catecholamines, heart rate, IL-6, and CRP concentrations.
Discussion
This study provides evidence that progression of carotid atherosclerosis can be prevented by the control of morning BP peak in hypertensive patients. In particular, at the same trend of day and night-time BP, decrease in morning BP peak was more effective in reducing CIMT than amelioration of clinic BP. These results suggest that excessive excursions of BP in the morning are harmful for the vascular tree and that morning BP should be considered a treatment target of therapy. In hypertensives, measuring CIMT has gained acceptance as a noninvasive, inexpensive method to assess the extent of atherosclerosis. 12 Moreover, higher CIMT is linked to prevalent stroke, coronary artery disease, and peripheral vascular disease, as well as incident myocardial infarction and stroke. 9 In lights of such evidence, the observation that MPϩ patients had higher CIMT compared with MPϪ patients suggests that surges of BP after arising convey a more relevant risk for cardiovascular events. As for the background for this association, the present study provides the first evidence of an association between morning BP peak, higher CIMT, inflammatory markers, and morning sympathetic overactivity.
Some available studies performed both in animal models of hypertension and in patients with essential hypertension have shown that sympathetic factors are involved in the progression of the cardiovascular structural alterations accompanying high BP. 13, 14 For example, by promoting vascular smooth muscle cell replication, activation of the nervous sympathetic system can favor the atherogenic process because smooth muscle cell replication precedes their migration to the intima and transformation to macrophages. 14 While confirming the association of sympathetic overactivity and atherosclerotic, our data show that the variation of BP was positively correlated with catecholamine urinary output during the morning period, whereas this association was not obtained during the day and night-time period.
Although a direct link between morning BP peak and acute cardiovascular events has not yet been established, it might be hypothesized that the surge in BP and morning sympathetic overactivity may be a factor predisposing to vulnerable coronary atherosclerotic plaques through an increase of inflammatory markers. Accordingly, we found that MPϩ patients had higher circulating levels of IL-18, IL-6, and CRP compared with MPϪ patients. Increases of BP have been shown to be significantly associated with elevated levels of circulating soluble intercellular adhesion molecule-1 and IL-6 in apparently healthy men, 15 supporting a possible role of hypertension as a proinflammatory stimulus. Inflammation not only contributes to the initiation and progression of atherosclerosis, but is also a key player in the cardiac outcome of acute coronary syndrome. 16 It might be speculated that the detrimental effect of morning BP peak in the atherosclerotic process might also be due to its ability to increase circulating IL-18, IL-6, and CRP levels. 15 The positive correlations we found between morning BP and inflammatory markers also suggest that the increase of the inflammatory process may be a link between morning BP and cardiovascular events in MPϩ patients. The results obtained after treatment also support a role for morning BP peak as a key factor predisposing toward atherosclerotic process, possibly through sympathetic overactivity and inappropriate cytokine secretion. At the same level of clinic BP reduction, patients with the highest level of morning BP had the highest level of inflammatory markers, the highest urinary catecholamine output, and the highest CIMT. In our study, 39% of drug-naïve hypertensive patients assigned to metoprolol and 41% assigned to carvedilol treatment obtained clinic BP values below the optimal value of Յ130/85 mm Hg. However, patients assigned to carvedilol had greater reduction of morning BP and larger regression of CIMT compared with patients assigned to metoprolol.
The CIMT regression seen in patients taking carvedilol seems to be related to the reduction in morning BP, as a relationship between day and night BP-lowering capacity of the drug and improved CIMT was not found. On the other hand, this association does not exclude that the additional beyond-BP-reduction effect of carvedilol (antioxidant activity as well as heart rate) has no effect on CIMT regression. On the other hand, we cannot exclude that, if the metoprolol dose was titrated to a comparably low heart rate, then similar reductions in CIMT may have occurred in both treatment groups, as heart rate is a major determinant of wall stress. However, in our cohort of hypertensive patients, carvedilol treatment produced a significant reduction in sympathetic activity as well as inflammatory markers. Thus, our data suggest that reduction in both morning sympathetic activation and morning BP peak may be the mechanism by which carvedilol retards atherogenesis progression by reduction in inflammatory markers. Although the degree of CIMT regression in our study is comparable with that of other classes of antihypertensive agents (angiotensin II receptor blockers), 17 there have been relatively few treatment trials involving CIMT measurements in hypertensive patients and no clear distinction among antihypertensive agents has been established. However, the benefical effects on CIMT obtained with carvedilol therapy may be related to the specificity of BP circadian rhythm of our patient.
Several studies suggest that sudden activation of the ␣-sympathetic activity is the primary mediator of the BP morning surge. 18, 19 In the Hypertension and Lipid
FIG. 1.
Changes (box plot representation) in clinic and morning blood pressure (BP) from baseline at the end of the metoprolol and carvedilol treatments. Box plot, a plot type that displays the 10th, 25th, 50th, 75th, and 90th percentiles as lines on a bar centered about the mean, and the 5th and 95th percentiles as error bars. The mean line and data points beyond the 5th and 95th percentiles can also be displayed. *P Ͻ .001 v metoprolol group.
FIG. 2.
Changes (box plot representation) of interleukin-6, interleukin-18, and C-reactive protein from baseline at the end of the metoprolol and carvedilol treatments. *P Ͻ .001 v metoprolol group.
Trial study, the ␣-blocker doxazosin reduced the morning increase in BP and sympathetic nervous activity in patients with essential hypertension. 20 Our data confirm these observations because treatment with carvedilol, a nonselective ␤-adrenoreceptor and selective ␣-adrenoreceptor blocker, 21 reduced both morning BP and sympathetic activity. In addition, the nonselective ␤-adrenergic antagonist carvedilol caused a greater reduction in both heart rate as well as urinary catecholamine output compared with the selective ␤ 1 -adrenergic receptor antagonist metoprolol. We postulate that these significant reductions in heart rate and urinary epinephrine, as well as norepinephrine output, resulted from blockade of prejunctional ␤ 2 -adrenergic receptors associated with sympathetic efferent neurons that release catecholamines. 22 Several placebo-controlled studies have demonstrated that nonselective ␤-adrenergic receptor blockade reduces plasma norepinephrine concentrations in patients with heart failure. 23, 24 Moreover, ␣-adrenergic blockade reduces the urinary catecholamine excretion in healthy subjects during exercise. 25 In light of these findings, we hypothesize that the greater reduction of urinary catecholamine output and heart rate in the carvedilol group may be determined by the different profile of carvedilol (combined ␤ 1 -, ␤ 2 -, and ␣ 1 -adrenergic receptor blockade versus selective ␤ 1 -adrenergic blockade by metoprolol). Furthermore, our data are in line with recent observation by Kario et al 26 that evidenced a reduction in the morning BP using ␣-adrenergic blockers. However, another determinant of the morning increase in BP may be the renin-angiotensin-aldosterone system activity. 27 Plasma renin and aldosterone activity has been reported to decrease gradually during the day, followed by a gradual increase overnight to a peak around the time of awakening. 27 Thus, we cannot exclude that other class of antihypertensive drugs (ie, angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers) may be dMBP ϭ diastolic morning blood pressure; E ϭ urinary epinephrine; HR ϭ heart rate; NE ϭ urinary norepinephrine; sMBP ϭ systolic morning blood pressure. * Log-transformed, † P Ͻ .05, ‡ P Ͻ .02, § P Ͻ .01.
FIG. 3.
Changes (box plot representation) of carotid intimal-medial thickness (CIMT) from baseline at the end of the metoprolol and carvedilol treatments. *P Ͻ .001 v metoprolol group.
potentially effective to reduce morning BP surge, as suggested by recent observations. 28 -30 Epidemiologic studies have demonstrated an elimination of the morning peak of disease onset in individuals receiving ␤-adrenergic blocking agents. 31, 32 Accordingly, our study evidenced that treatment with carvedilol was associated with reduction of both morning BP and CIMT, as well as inflammatory markers. Moreover, changes of CIMT were independently associated with changes of morning BP peak, morning urinary catecholamines, IL-6, and CRP concentrations, after carvedilol treatment. It has been demonstrated that catecholamines play a role in the production of and increase in plasma IL-6 levels. 25, 33 These studies implicate both the ␤-adrenergic and ␣-adrenergic pathway for IL-6 activation, because ␤-adrenergic and ␣-adrenergic agonists can mimic the effects of catecholamines, whereas ␤-adrenergic and ␣-adrenergic antagonists block the IL-6 response. The finding that ␤-adrenergic and ␣-adrenergic blockade significantly reduced IL-6 is noteworthy. The IL-6 is an important cytokine involved in a number of biological processes, including the synthesis of acute phase proteins and the regulation of the immune or inflammatory reaction to atherosclerosis progression. 34 Thus, our data suggest the ability of carvedilol to reduce both ␤-and ␣-adrenergic-mediated inflammatory reaction in carotid artery of patients with morning BP peak. The majority of acute cardiovascular events, whether they occur during sleep or wakefulness, are now known to result from disrupted atherosclerotic plaques. 35 Various evidence support the role of inflammation within or surrounding the plaque as a precursor of atherosclerosis progression and plaque rupture. 16 Higher CIMT, circulating inflammatory markers, and morning sympathetic overactivity coexist in hypertensive patients with morning BP peak, and might contribute to their increased cardiovascular risk. Amelioration of morning BP provides superior efficacy for atherosclerosis regression in the distal common carotid artery at 1 year compared with amelioration of clinic BP. These results support the hypothesis that control of excessive morning BP excursions may provide clinical benefit in hypertensive patients.
